{"id":"insulin-lispro-mix50","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin Lispro is a rapid-acting human insulin analog created by reversing the order of the last two amino acids (lysine and proline) of human insulin, allowing faster absorption and onset of action. Mix50 is a 50/50 premixed formulation combining 50% rapid-acting insulin lispro with 50% insulin lispro protamine suspension (intermediate-acting), designed to provide both mealtime and basal insulin coverage in a single injection. This combination mimics physiologic insulin secretion patterns in diabetic patients.","oneSentence":"Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:22.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01613807","phase":"PHASE4","title":"Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-10","conditions":"Gestational Diabetes Mellitus","enrollment":40},{"nctId":"NCT01773473","phase":"PHASE4","title":"Comparison of Insulin Mix25 Versus Mix50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":403},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01398670","phase":"PHASE3","title":"Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2012-02","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT01400789","phase":"PHASE1","title":"Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"","conditions":"Bioequivalence in Healthy Subjects","enrollment":""},{"nctId":"NCT00971997","phase":"PHASE4","title":"A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT01303042","phase":"NA","title":"Efficacy of Insulin Lispro Mix 50/50 Therapy","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00191581","phase":"PHASE3","title":"Local Registration Trial in China Humalog Mix 50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585-50"],"phase":"marketed","status":"active","brandName":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}